Silodosin Dosing and Contraindications Based on Renal Function
Silodosin is contraindicated in severe renal impairment (creatinine clearance <30 mL/min), requires dose reduction to 4 mg once daily in moderate renal impairment (CrCl 30-50 mL/min), and can be given at the standard 8 mg once daily dose in mild renal impairment (CrCl 50-80 mL/min) or normal renal function. 1
Dosing Algorithm by Creatinine Clearance
Normal to Mild Renal Impairment (CrCl ≥50 mL/min)
- Dose: 8 mg orally once daily with a meal
- No adjustment needed 1
Moderate Renal Impairment (CrCl 30-50 mL/min)
- Dose: 4 mg orally once daily with a meal
- Rationale: Plasma concentrations (AUC and Cmax) are approximately 3 times higher in moderate renal impairment, with doubled half-life 1
- Monitor closely for adverse events 1
Severe Renal Impairment (CrCl <30 mL/min)
- CONTRAINDICATED - do not prescribe 1
Additional Contraindications
Beyond renal function, silodosin is contraindicated in:
- Severe hepatic impairment (Child-Pugh score ≥10) 1
- Concomitant use with strong CYP3A4 inhibitors (ketoconazole, clarithromycin, itraconazole, ritonavir) - these increase silodosin exposure 3.2-fold 1
- History of hypersensitivity to silodosin or any ingredient 1
Important Clinical Considerations
Hepatic impairment: No dose adjustment needed for mild-to-moderate hepatic dysfunction (Child-Pugh score <10) 1, 2
Administration: Always take with a meal. For patients unable to swallow capsules, the powder can be sprinkled on applesauce and swallowed immediately without chewing, followed by 8 oz of water 1
Cardiovascular safety: Silodosin's high α1A-selectivity (versus α1B-receptors in blood vessels) provides excellent cardiovascular tolerability with minimal orthostatic hypotension risk compared to non-selective alpha-blockers 2, 3. However, patients should still be cautioned about dizziness when initiating therapy 1.
Common pitfall: The selective α1A-receptor blockade that provides cardiovascular safety also results in retrograde ejaculation/ejaculatory disorders in 0.85-34.4% of patients 3 - counsel patients about this expected effect before starting therapy.